Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$4.27 -5.1%	$3.89	$1.89 ▼ $5.82	$1.34B	0.65	6.94 million shs	5.03 million shs
CDTX Cidara Therapeutics	$62.00	$47.34	$10.14 ▼ $66.94	$1.57B	1.18	498,442 shs	291,955 shs
CVAC CureVac	$5.47 +0.7%	$5.31	$2.37 ▼ $5.72	$1.22B	2.53	708,683 shs	1.11 million shs
RNAC Cartesian Therapeutics	$11.33 +2.1%	$11.52	$8.46 ▼ $26.50	$288.62M	0.44	58,201 shs	31,482 shs

10 Stocks Set to Soar in Fall 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	+5.88%	+3.69%	+12.22%	+114.29%	+67.91%
CDTX Cidara Therapeutics	0.00%	-0.74%	+22.70%	+220.25%	+424.98%
CVAC CureVac	-0.18%	-0.55%	-0.55%	+60.18%	+65.55%
RNAC Cartesian Therapeutics	+5.41%	-11.06%	-16.67%	+8.82%	-16.98%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABCL AbCellera Biologics	3.2311 of 5 stars	4.5	1.0	0.0	2.9	3.3	0.0
CDTX Cidara Therapeutics	3.4106 of 5 stars	2.6	2.0	4.6	2.7	1.7	0.0
CVAC CureVac	3.9726 of 5 stars	3.1	3.0	4.9	2.1	0.0	1.3
RNAC Cartesian Therapeutics	1.9087 of 5 stars	3.4	0.0	0.0	2.8	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABCL AbCellera Biologics	3.00	Buy	$8.00	87.35% Upside
CDTX Cidara Therapeutics	3.11	Buy	$64.14	3.46% Upside
CVAC CureVac	2.20	Hold	$6.83	24.92% Upside
RNAC Cartesian Therapeutics	2.80	Moderate Buy	$40.00	253.05% Upside

Current Analyst Ratings Breakdown

Latest RNAC, CDTX, ABCL, and CVAC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	CDTX Cidara Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/8/2025	ABCL AbCellera Biologics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $7.00
8/8/2025	CDTX Cidara Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$59.00 ➝ $66.00
8/8/2025	CDTX Cidara Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$53.00 ➝ $74.00
8/8/2025	CDTX Cidara Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$54.00 ➝ $74.00
7/14/2025	ABCL AbCellera Biologics	KeyCorp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$5.00 ➝ $10.00
7/9/2025	CDTX Cidara Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$69.00
7/9/2025	RNAC Cartesian Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$38.00
7/7/2025	ABCL AbCellera Biologics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/7/2025	ABCL AbCellera Biologics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$5.00
6/30/2025	CDTX Cidara Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$59.00

(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABCL AbCellera Biologics	$28.83M	44.26	N/A	N/A	$3.37 per share	1.27
CDTX Cidara Therapeutics	$1.27M	1,238.05	N/A	N/A	$19.76 per share	3.14
CVAC CureVac	$579.18M	2.12	$0.88 per share	6.22	$3.36 per share	1.63
RNAC Cartesian Therapeutics	$38.91M	7.57	N/A	N/A	($0.10) per share	-113.30

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABCL AbCellera Biologics	-$162.86M	-$0.55	N/A	N/A	N/A	-511.88%	-16.17%	-12.24%	N/A
CDTX Cidara Therapeutics	-$169.83M	-$11.13	N/A	N/A	N/A	N/A	-50.81%	-42.46%	N/A
CVAC CureVac	$175.50M	$0.92	5.95	N/A	N/A	35.44%	30.89%	25.54%	8/13/2025 (Estimated)
RNAC Cartesian Therapeutics	-$77.42M	-$52.83	N/A	N/A	N/A	N/A	N/A	-6.36%	N/A

Latest RNAC, CDTX, ABCL, and CVAC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/21/2025	Q2 2025	CVAC CureVac	-$0.15	N/A	N/A	N/A	$4.27 million	N/A
8/7/2025	Q2 2025	ABCL AbCellera Biologics	-$0.17	-$0.12	+$0.05	-$0.12	$7.55 million	$17.08 million
8/7/2025	Q2 2025	CDTX Cidara Therapeutics	-$1.87	-$1.65	+$0.22	-$1.65	N/A	N/A
8/7/2025	Q2 2025	RNAC Cartesian Therapeutics	-$0.76	$0.50	+$1.26	$0.50	$0.77 million	$0.30 million
5/22/2025	Q1 2025	CVAC CureVac	-$0.16	-$0.24	-$0.08	-$0.24	$4.27 million	$0.94 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABCL AbCellera Biologics	N/A	N/A	N/A	N/A	N/A
CDTX Cidara Therapeutics	N/A	N/A	N/A	N/A	N/A
CVAC CureVac	N/A	N/A	N/A	N/A	N/A
RNAC Cartesian Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABCL AbCellera Biologics	N/A	11.07	11.07
CDTX Cidara Therapeutics	N/A	16.45	3.87
CVAC CureVac	0.05	7.65	7.64
RNAC Cartesian Therapeutics	N/A	13.33	12.34

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABCL AbCellera Biologics	61.42%
CDTX Cidara Therapeutics	35.82%
CVAC CureVac	17.26%
RNAC Cartesian Therapeutics	86.95%

Insider Ownership

Company	Insider Ownership
ABCL AbCellera Biologics	28.90%
CDTX Cidara Therapeutics	7.64%
CVAC CureVac	N/A
RNAC Cartesian Therapeutics	60.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABCL AbCellera Biologics	500	298.83 million	212.47 million	Optionable
CDTX Cidara Therapeutics	90	25.36 million	23.42 million	No Data
CVAC CureVac	880	224.34 million	N/A	Optionable
RNAC Cartesian Therapeutics	64	26.00 million	10.32 million	Optionable

RNAC, CDTX, ABCL, and CVAC Headlines

Recent News About These Companies

Cartesian (RNAC) Q2 Revenue Drops 99%

August 9 at 2:40 AM | theglobeandmail.com

Cartesian Therapeutics Reports Positive Q2 2025 Earnings

August 8, 2025 | tipranks.com

Cartesian Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

August 7, 2025 | taiwannews.com.twT

Cartesian Therapeutics (RNAC) to Release Quarterly Earnings on Thursday

August 7, 2025 | marketbeat.com

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Consensus Recommendation of "Moderate Buy" from Analysts

August 4, 2025 | marketbeat.com

Cartesian Therapeutics, Inc. (RNAC) Moves 9.9% Higher: Will This Strength Last?

July 24, 2025 | zacks.com

Wedbush Initiates Coverage of Cartesian Therapeutics (RNAC) with Outperform Recommendation

July 9, 2025 | msn.com

We're Not Very Worried About Cartesian Therapeutics' (NASDAQ:RNAC) Cash Burn Rate

June 21, 2025 | finance.yahoo.com

Cartesian Therapeutics holds annual stockholders meeting

June 17, 2025 | investing.com

Cartesian Therapeutics Announces New Employment Inducement Grants

June 3, 2025 | globenewswire.com

BTIG Sticks to Their Buy Rating for Cartesian Therapeutics (RNAC)

June 2, 2025 | theglobeandmail.com

Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis

May 30, 2025 | globenewswire.com

Cartesian Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ

May 13, 2025 | manilatimes.netM

Analysts Are Bullish on Top Healthcare Stocks: Harrow Health (HROW), Cartesian Therapeutics (RNAC)

May 11, 2025 | theglobeandmail.com

Cartesian Therapeutics (RNAC) Gets a Buy from Mizuho Securities

May 11, 2025 | theglobeandmail.com

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

May 11, 2025 | finance.yahoo.com

Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025 | globenewswire.com

Why Cartesian Therapeutics, Inc. (RNAC) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential

May 5, 2025 | insidermonkey.com

Cartesian Therapeutics Announces New Employment Inducement Grants

May 2, 2025 | globenewswire.com

Cartesian Therapeutics management to meet with BTIG

April 26, 2025 | markets.businessinsider.com

Why Cartesian Therapeutics, Inc.’s (RNAC) Stock Is Down 5.62%

April 22, 2025 | aaii.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNAC, CDTX, ABCL, and CVAC Company Descriptions

AbCellera Biologics NASDAQ:ABCL

$4.27 -0.23 (-5.11%)

Closing price 04:00 PM Eastern

Extended Trading

$4.31 +0.04 (+0.96%)

As of 07:58 PM Eastern

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Cidara Therapeutics NASDAQ:CDTX

$62.00 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$63.00 +1.00 (+1.62%)

As of 06:58 PM Eastern

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

CureVac NASDAQ:CVAC

$5.47 +0.04 (+0.74%)

Closing price 04:00 PM Eastern

Extended Trading

$5.50 +0.03 (+0.46%)

As of 06:25 PM Eastern

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Cartesian Therapeutics NASDAQ:RNAC

$11.33 +0.23 (+2.07%)

Closing price 04:00 PM Eastern

Extended Trading

$11.36 +0.03 (+0.22%)

As of 04:10 PM Eastern

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time